Skip to content

H.R. 8857 · 119th Congress (2025–2027)

Next GEN Act of 2026

To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.

CRS summary not yet available.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is H.R. 8857’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. Joseph D. Morelle (D-NY-25)
Cosponsors
4 cosponsors

3 original · 1 later

  1. Rep. Josh Gottheimer (D-NJ-5)· Original · May 15, 2026
  2. Rep. Thomas H. Kean, Jr. (R-NJ-7)· Original · May 15, 2026
  3. Rep. August Pfluger (R-TX-11)· Original · May 15, 2026
  4. Rep. Donald G. Davis (D-NC-1)· Later · Aug 27, 2026
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest

    Referred to committee

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Sources

Committees

  1. HouseEnergy and CommerceReferred May 15, 2026
  2. HouseWays and MeansReferred May 15, 2026

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (3)
  1. Next GEN Act of 2026

    Display title, Short title · Introduced in House

  2. To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.

    Official title · Introduced in House

  3. Next Generation Medicines Act of 2026

    Short title · Introduced in House